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In Helsinn v. Teva, the Supreme Courtheld that Congress
did not alter the meaning of "on sale" when it enacted the LeahySmith America In vents Act and, therefore, an inventor'ssale of an
invention to a thirdparty who is obligated to keep the invention
confidential may qualify as prior art. The Court relied upon
precedent which suggested that a sale or offer of sale need not
make an invention available to the public to qualify as priorart.
Instead, the on-sale bar only required that the invention be the
subject of a commercial offer for sale and readyforpatenting.
* J.D. Candidate, Loyola University Chicago School of Law, 2020.
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Unfortunately, the Court's nine-page opinion fell short of
expectations. Not only was the Court's decision at odds with the
legislative historyof the Leahy-Smith America Invents Act, it will
undoubtedly create unnecessary confusion regardingthe proper
implementation of the on-sale bar. Further, this decision interferes
with Congressionalintent to harmonize the United States patent
system with those of other countries. Most importantly, this
decision will have a particularlydetrimentaleffect on small and
midsize pharmaceutical companies who frequently rely on
partnerships with larger, more profitable entities in order to
continue with theirresearch anddevelopment of new drugs.
INTRODUCTION
When Helsinn v. Teva finally reached the Supreme Court,
there was anticipation that this case could offer some much-needed
clarification on the true interpretation of the on-sale bar in the
wake of the passage of the Leahy-Smith America Invents Act
("AIA").' Congress had significantly changed patent laws under the
AIA including some minor yet noteworthy changes to the on-sale
bar.2 Not only was the on-sale bar no longer limited to commercial
activity within the United States, but the new catchall. provision
suggested that in order to constitute prior art a sale must make the
claimed invention "available to the public."' Such changes were
implemented with the intent to improve the United States patent
system and harmonize it with the patent laws of other countries.'
Unfortunately, the Federal Circuit's decision in Helsinn
appeared to contradict such intentions.s The Federal Circuit held
that any sale, whether public or private, may render a patent
Hans Sauer, WhyHelsinn v. Teva CreatesInscrutable UncertaintyAbout
theScope ofPriorArtInsteadofConfirmingLongstandingLaw,IPWATCHDOG
(Feb. 5, 2019), https://www.ipwatchdog.com/2019/02/05/helsinn-v-teva-createsinscrutable-uncertainty-scope-prior-art-instead-confirming-longstandinglaw/id= 105 953/ (noting the need for clarity regarding the implementation of the
on-sale bar for business and patent owners under current AIA law).
2 Brief for Petitioner at 3-4, Helsinn Healthcare S.A. v. Teva Pharm. USA
Inc., 139 S. Ct. 628 (2019) (No. 17-1229) (describing how Congress modified the
on-sale bar with the removal of the geographical requirement as well as the
addition of the phrase "or otherwise available to the pubic").
1

4

1d

s Helsinn, 855 F.3d 1356, 1371 (Fed. Cir. 2017) (holding that "after the AIA,
if the existence of the sale is public, the details of the invention need not be
publicly disclosed in the terms of the sale").

2019

Helsinn v. Teva: A Big Blow to Small Pharma

591

invalid.' However, the Federal Circuit refrained from answering
whether the AIA had changed the meaning of the on-sale bar.' The
Federal Circuit's hesitation in answering this question only
increased the confusion surrounding the true interpretation of the
on-sale bar in light of the AIA. In particular, the Federal Circuit's
holding created a great deal of uncertainty for small and midsize
pharmaceutical companies who often rely on confidential deals
with business partners to finance the research and development of
new drugs.'
Thus, when the Supreme Court granted certiorari on the
single issue of whether a confidential sale of an invention to a third
party would qualify as prior art under the AIA, there was hope
that the Supreme Court could shed some light on questions left
unanswered by the Federal Circuit.' Unfortunately, the Court's
holding further exacerbated the problem created by the Federal
Circuit's decision.o The Court's unanimous yet relatively short
opinion hardly delved into the drafting history of the AIA.n By
failing to adequately consider the drafting history, which led to
significant changes in the language of the on-sale bar, the Supreme
Court thwarted efforts to streamline patent laws in the United
States and potentially jeopardized the research and development
of innovative drugs fueled by the efforts of small and midsized
pharmaceutical companies.
Part I of this Note describes the history and development of
the AIA. In particular, Part I will examine the status of the on-sale

6

Id.

Helsinn, 855 F. 3d at 1368.
Brief for Massachusetts Biotechnology Council ("MassBio") as Amicus
Curiae Supporting Petitioner at 13, Helsinn, 139 S. Ct. 628 (explaining how the
high cost of drug development and limited resources leads many small and
midsize biotechnology companies to rely on partnerships with business partners
to support their research and development).
' Sauer, supra note 1 (noting that the Supreme Court granted Helsinn
certiorari on the sole issue of whether confidential sales by inventors to third
parties may constitute prior art); see also Helsinn, 855 F. 3d at 1368 (refraining
from answering whether the AIA had changed the meaning of the on-sale bar
and therefore deciding the case "more broadly than necessary").
"o Id. (lamenting the "host of problems" that Helsinn would create which
were "never the law before or after the AIA").
" Helsinn, 139 S. Ct. at 634 (limiting discussion of Congressional intent in
enacting the on-sale bar language of the AIA. by stating that "the addition of
'otherwise made available to the public' is simply not enough of a change for us
to conclude that Congress intended to alter the meaning of the reenacted term
'on sale' ").
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bar before and after the passage of the AIA. Part II discusses the
factual and procedural history of Helsinn and the Supreme Court's
decision. Part III argues that the Court's decision runs contrary to
the drafting history of the AIA and ignores Congressional intent.
Finally, Part IV explains the potential negative implications of this
decision for research and development efforts by small and midsize
pharmaceutical companies. Part V offers a brief conclusion.
I. THE HISTORY AND DEVELOPMENT OF THE ON-SALE
BAR
Congress is authorized by the Constitution "[to] promote
of Science and useful Arts, by securing for limited
progress
the
Times to Authors and Inventors the exclusive Right to their
respective Writings and Discoveries."2 The United States patent
system is therefore a delicate balance between rewarding inventors
while preventing monopolization." In the interest of striking this
balance, Congress has included some version of the on-sale bar in
"every patent statute since 1836."l4 The on-sale bar was created
with the intention of preventing situations wherein an inventor
may profit from his or her invention and only remove it from the
public domain when threatened by competition."
Patent law was dramatically changed in 2011 when
Congress enacted the AIA in order to "replace the existing first-toinvent patent system with a first-to-file system."1 6 This was done
with the intention of bringing the United States patent system in
harmony with other major patent systems around the world." A
major development in the law included changes to the definition
*ofprior art.18 The AIA altered the definition of prior art in three
Art. 1, §8, cl. 8.
" Pfaff v. Wells Electronics, Inc., 525 U.S. 55, 63 (1998) (explaining that
"the patent system represents a carefully crafted bargain that encourages both
the creation and the public disclosure of new and useful advances in technology,
in return for an exclusive monopoly for a limited period of time.").
14 Id. at 65 (noting that the Patent Act of 1836 was the first statute to include
an on on-sale bar).
" Pennock v. Dialogue, 27 U.S. 1, 13 (1829) (describing how it would be
unfair to allow an inventor to exclude knowledge previously available to the
public even though he has already made and sold his invention publicly for
many years).
16 Brief for Petitioner at 5, Helsinn, 139 S. Ct. 628 (noting that the AIA
"transformed the Nation's patent laws").
1 Id. (discussing how the AIA altered the definition of prior art).
12

SId. at 6.
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major ways including: (1) the addition of the catchall phrase "or
otherwise available to the public," (2) removal of the geographical
limitations for patent invalidity and (3) replacing the term
"invention" with the phrase "claimed invention." 9 This Part will
discuss the implementation of the on-sale bar before and after the
passage of the AIA.
A. The State of the On-sale BarPriorto the America Invents Act
Prior to the passage of the Patent Act of 1836 which was the
first federal Patent Act to include some form of an on-sale bar,
Pennock v. Dialoguewas decided. 20 The Pennockopinion included
an important discussion of the negative consequences of an
inventor's decision to commercially exploit his or her invention
prior to applying for a patent. 2L In Pennock, the Court reasoned
that an inventor may not "acquire good title to a patent, if he
suffers the thing invented to go into public use, or to be publicly
sold for use, before he makes application for a patent." 2 2 The Court
repeatedly emphasized that it is the fact that an invention has been
made publiclyavailable which invalidates the patent. 23
Under the Patent Act of 1952, the on-sale bar stated that a
patent may be invalid if an "invention was patented or described
in a printed publication in this or a foreign country or in public use
or on sale in this country, more than one year prior to the date of
the application for patent in the United States." 24 The language of
the on-sale bar in the Patent Act of 1952 therefore remained true
to the goal of rewarding innovation while "avoiding monopolies
that unnecessarily stifle competition." 2 5 The Supreme Court
analyzed the implications of this overarching goal of patent law in
Bonita Boats, Inc. v. Thunder Craft Boats, Inc.. 2 The Court
19

Id.

See Pfaff 525 U.S.at 65; see also Pennock, 27 U.S. at 13.
See Pennock, 27 U.S. at 8 (noting that it is "directly contrary" to the
purposes of patent law when an inventor attempts to withdraw his invention
from the common stock after the public has already had full possession of it).
22 Id. at 10.
23 Id. at 20 (describing how under the common law of
England, letters
patent were unavailable for the protection of articles in public commerce at the
time of the application and this embodied in the patent laws passed in this
country).
24 35 U.S.C 102(b) (2006).
25 See Pfaf, 525 U.S.
at 63.
26 Bonita Boat, Inc. v. Thunder Craft Boats, Inc.,
489 U.S. 141, 156-157
(1989) (holding that "a state law that substantially interferes with the enjoyment
2

21
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reiterated the reasoning in Penncock that "the public sale of an
unpatented article has acted as a complete bar to federal protection
of the idea embodied in the article thus placed in public
commerce."2 7 Again, the Court emphasized that a key disqualifying
factor for patentability was the public nature of the sale.
When the Supreme Court decided Pfaff v. Wells
Electronics, Inc. in 1998, however, it shifted the focus of the onsale bar analysis. 28 The Court held that the on-sale bar applied
when an invention was "the subject of a commercial offer for sale"
and "ready for patenting" for more than one year before the
inventor filed his or her patent application. 29 Notably, this
standard is completely devoid of any discussion of whether the sale
must disclose the claimed invention to the public as was the case
in Pennock and Bonita Boats.' Nevertheless, this has been the
standard for the pre-AIA on-sale bar since its inception." The
Court later clarified in Medicines Company v. Hospirathat mere
preparations for commercial sales did not invalidate a patent
under the pre-AIA on-sale bar.3 2
B. The Development andImplementation of the America Invents
Act
While the AIA was enacted in 2011, efforts to bring about
these major changes to the United States patent system began as
early as 1982." A "nationwide consensus" had been developing
of an unpatented utilitarian or design conception which has been freely disclosed
by its author to the public at large impermissibly contravenes the ultimate goal
of public disclosure and use which is the centerpiece of federal patent policy").
27 Id. at 149.
28 See Brief for Petitioner at 5, Helsinn, 139 S. Ct. 628 (noting that the
holding in Pfaff"was in tension with this Court's repeated statements that the
on-sale bar reached the 'public sale of an unpatented article' that placed the
article 'in public commerce' ").
29 See Pfaff, 525 U.S. at
67.
o Id. at 68 (finding that the plaintiff's patent was invalid under the on-sale
bar because his invention was ready for patenting prior to the critical date
without considering whether the sale made the invention available to the
public).
31 See Helsinn, 139 S. Ct. at 634 (clarifying that the Court had not
previously addressed whether a sale must disclose the claimed invention to
public in order to invalidate a patent under the on-sale bar).
2 Medicines Co. v. Hospira, Inc., 827 F.3d 1363, 1377 (holding that "the
mere stockpiling of a patented invention by the purchaser of manufacturing
services does not constitute a 'commercial sale' under §102(b)").
for The Intellectual 'Property Law Association of Chicago
13 Brief
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amongst the patent community for the United States to "move to a
first-inventor-to file patent system."3 4 Therefore, the Senate
created an Intellectual Property Subcommittee of the Senate
Judiciary Committee in 2005.11 Congress consulted those in the
patent community as well as the United States Patent and
Trademark Office ("USPTO") in reforming the United States
patent system.3 6
Alongside other significant changes, the Patent Reform Act
of 2007 specifically altered the scope of prior art. 7 The Act clarified
that prior art must be "available to the public"'38 The Patent
Reform Act of 2009 reiterated this idea as well.3 ' The Senate bill
finally passed in 2011.40 In its consideration of the AIA, the House
Report stated that the Act "simplifies how prior art is determined,
provides more certainty, and reduces the cost associated with filing
and litigating patents."' The House and Senate subsequently
passed the AIA.4 2
Prior to the passage of the bill, members of Congress
debated the particular language of the on-sale bar at great length.4 3
The final Committee Report for the AIA cited floor remarks from
Senator Jon Kyl who explained the Congressional intent behind
changing the language of the on-sale bar.4 He stated that Congress
wished to do away with the "secret-sale and private use forfeiture
doctrines" which served as "traps for unwary inventors" imposing
"extreme results to no real purpose."4 5 Therefore, the new
§102(a)(1) purposely limited the scope of non-patent prior art to
that which is "available to the public." 4 6
Furthermore, the addition of the catchall provision aligned
("IPLAC") as Amicus Curiae Supporting Petitioner at 6, Helsinn, 139 S. Ct. 628.
34
3s

Id. at7.
Id. at 8.

Id
Id. at 9.
38 Id.
36

3

39

Id

Id. at 11.
Id.
42 Id.
43 See Brief for Petitioner at 7, Helsinn, 139 S. Ct. 628 (explaining that the
phrase "or otherwise made available to the public" originated in the Senate
Judiciary Committee and was included in the House Bill as well).
44 Joe Matal, A Guide to the Legislative Historyof the America In vents Act:
Part1 offfi 21 FED. CIR. B.J. 435, 466-469.
45 Id
46 Id.
40
41
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with Congressional intent to harmonize the United States patent
system with that of its international counterparts. 7 Prior to the
passage of the AIA, the United States was the only patent system
48
which did not abide by the first-inventor-to-file principle.
Moreover, most other patent systems outside of the United States
required that a claimed invention be made public in order to
constitute prior art.49 Thus, by switching to a first-inventor-to-file
system and adding the phrase "or otherwise available to the
public," Congress made United States patent law consistent with
the laws of other major patent systems around the world.
Additionally, the USPTO issued revised guidelines for
0
examining patent applications after the passage of the AIA. The
USPTO instructed examiners that a sale under the AIA "must
make the invention available to the public" to qualify as prior art."
This interpretation was later included in the Manual of Patent
Examining Procedures.5 2 Therefore, the USPTO respected
Congressional intent in its application of the post-ALA on-sale bar.
II. HELSINN V. TEVA
The drafting history of the AIA strongly suggests that
Congress intentionally and thoughtfully included this catchall
provision in the on-sale bar of the AIA. Yet, despite the addition
of this new language in the on-sale bar of the AIA, neither the
Federal Circuit nor the Supreme Court interpreted the new
statutory language prior to Helsinn.3 When Helsinn filed a writ of
certiorari in February 2018, the Supreme Court finally had the
See Brief for Petitioner at 6, Helsinn, 139 S. Ct. 628 (noting that "the
AIA's fundamental innovation was to replace the existing first-to-invent patent
system with a first-inventor-to-file system which would bring "the American
patent system in line with the world's other major patent systems").
4

48

Id.

Brief for Congressman Lamar Smith as Amicus Curiae Supporting
Petitioner at 6, Helsinn, 139 S. Ct. 628 (clarifying that other countries have long
interpreted "available to the public" to "preclude subject matter that remains
confidential or otherwise secret from constituting prior art and being used to
invalidate a patent").
so See Brief for Petitioner at 8, Helsinn, 139 S. Ct. 628.
49

51

Id.

Id.
5 Joseph A. Herndon & James L. Korenchan, Pre-AIA andPostALA Issues
Presented By The On-Sale Bar, LAW360 (Aug. 11, 2016, 12:13 PM),
https://www.law360.com/articles/825887/pre-aia-and-post-aia-issuespresented-by-the-on-sale-bar; see also Helsinn, 139 S. Ct. at 634.
52
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opportunity to offer some insight into the true interpretation of the
new language.5 4
The Supreme Court granted certiorari in June 2018 on the
sole issue of whether a confidential sale by an inventor to a third
party places the invention "on sale" within the meaning of
§ 102(a).ss This Part will describe the facts and procedural history
of the case and conclude with a discussion of the Court's opinion.
A. FactsandProceduralHistoryin the Lower Courts
The patents at issue in this case cover dosages of
palonosetron which is used in treating chemotherapy-induced
nausea and vomiting. 6 Scientists working under a company
named Syntex (U.S.A), Inc. ("Syntex") in California began the
original research into the usage of palonosetron for preventing
nausea and vomiting." Syntex was later acquired by Roche, a
Swiss pharmaceutical company. Petitioner Helsinn Healthcare
S.A. ("Helsinn") is also a Swiss pharmaceutical company and when
it became aware that Roche had decided to terminate its
palonosetron development project, it entered into a license
agreement with Roche and continued the development of
palonosetron into a pharmaceutical product. 59 In order to proceed
with development of the product, Helsinn partnered with Oread,
Inc. ("Oread").6 0 However, Oread went out of business in the
middle of Phase III trials of the drug.6 1
Helsinn then found a commercial partner in MGI Pharma,
Inc. ("MGI"), a Minnesota company.6 2 They entered into a license
agreement and a supply and purchase agreement with MGI.6 3 MGI
was not buying a product but rather the rights to participate in the
development effort to potentially have a product in the future.6 4
MGI is a publicly traded company required to file SEC disclosures
54

Petition for Writ of Certiorari, Helsinn, 139 S. Ct. 628 (2019) (No. 17-

1229).
Sauer, supra note 1.
Helsinn Healthcare S.A. v. Dr. Reddy's Labratories Ltd., No. 11-3962,
2016 WL 832089, at *1 (D.N.J 2016).
s7 Id. at 5.
5 Id. at 8.
so Id. at 10-12.
60 Id. at 14-15.
61 Id
62 Id. at
2 7.
5s

56

63

Id.

64

Idat28.
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and so in its published SEC Form 8-K it reported these agreements
with Helsinn.s Palonosetron was mentioned in the public
66
disclosures but the exact dosage was redacted.
Teva
respondents
suit against
brought
Helsinn
Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA,
Inc. ("Teva") alleging infringement of its patents including the '219
patent. 67 In response, Teva argued that the '219 patent was invalid
under the on-sale bar.68 The District Court held that the under the
AIA the claimed invention must be made available to the public in
order to trigger the on-sale bar.69 In making this determination, the
court considered the statutory language, UPSTO guidelines, the
legislative history of the AIA, and public policy implications.o
Thus, the Court found that because the public disclosure of the
agreements between Helsinn and MGI did not disclose exact
dosage of palonosetron, the invention was not "on sale" prior to the
critical date."
The Federal Circuit reversed the District Court's holding
and held that there was a sale under the standard set by Pfaffgiven
that invention was ready for patenting." However, the Federal
Circuit refrained from engaging in a discussion as to whether the
3
AIA had altered the meaning of the on-sale bar. The Supreme
74
Court granted certiorari on this issue alone.
B. The Court's Opinion
The Court delivered a unanimous opinion holding that a
confidential sale of an invention to a third party places the
5
invention "on sale" within the meaning of §102(a). The Court's

6s
66
67

Id. at 29.
Id
Id. at 1.

68

Id.

69

Id. at 45.
I[d

70

1 Id. at 52.

See Helsinn, 855 F. 3d at 1371 (holding the invention was ready for
patenting as it was reduced to practice prior to the critical date).
7 Id. at 1368 (refraining from deciding the case "more broadly than
necessary').
74 Sauer, supra note 1.
7 See Helsinn, 139 S. Ct. at 634 (holding that Congress had not altered the
meaning of "on sale" with, the passage of the AIA and therefore an inventor's
confidential sale constitutes prior art under §102(a)).
72
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reasoning began with a discussion of the standard set by Pfaff7 6
While the Court acknowledged that it had never before attempted
to answer "the precise question presented in this case," it was
guided by its precedents in holding that a sale or offer of sale need
not make an invention available to the public." The Court
emphasized that in prior cases public disclosure was not relevant
in analyzing whether or not an offer for a sale had occurred."
Furthermore, the Court noted that the Federal Circuit had
previously held that a confidential sale may invalidate a patent.7 9
In the Court's opinion, the "well settled pre-AIA precedent"
suggested that Congress had not altered the meaning of the AIA
when it reenacted the same language regarding sales and offers for
sale as prior art."o The Court reasoned that if Congress had
intended to alter the meaning of what kinds of sales qualified as
prior art, this would not have been accomplished with the subtle
addition of the phrase "or otherwise available to the public.""
Therefore, the Court affirmed the judgment of the Federal
Circuit. 82

'III. THE HOLDING OF HELSINNRUNS CONTRARY TO
THE DRAFTING HISTORY OF THE AMERICA INVENTS
ACT
The Court's relatively short opinion in Helsinnoverstepped
its authority when it largely ignored the plain-text interpretation
of the on-sale bar of the AIA, as well as the drafting history and
Congressional intent behind the language of the on-sale bar.
Congress, not the Supreme Court, was granted the authority by the
Constitution to regulate patent law.84 The duties of the Supreme
76

Id. at 632.

" Id. at 633.
78

Id

Id. at 633-634.
8' Id. at 634.
82 Id.
80

8
Eileen McDermott, IndustryInsiders: OpinionsMixed in the Aftermath
of Supreme Court Holding in Helsinn, IP WATCHDOG (Jan. 23, 2019),
http://www.ipwatchdog.com/2019/01/23/industry-insiders-aftermath-supremecourt-helsinn/id=105527/ (quoting the opinion of retired Chief Judge Paul
Michel of the United States Court of Appeals for the Federal Circuit that the
Supreme Court as the tendency "treat patent law as if it were largely common
law" and therefore "legislate patent law from the bench").
84 Id. (clarifying that patent law is a "wholly statutory regime" and the
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Court are limited to the interpretation of the statutory language
enacted by Congress." Thus, the Court's decision does little more
than "legislate patent law from the bench" and instead further
6
muddles the true interpretation of the on-sale bar.
A. The Court'sDecisionis Inconsistent with the Plain-text
Interpretationof the Post-AIA On-sale Bar Language
The current language of on-sale bar states that "a person
shall be entitled to a patent unless the claimed invention was
patented, described in a printed publication, or in public use, on
sale, or otherwise available to the public before the effective filing
date of the claimed invention."87 Every category of prior art within
the current language of the on-sale bar "intrinsically" shares the
characteristic of disclosing the claimed invention to the public in
some manner." In this way, "the noscitura sociis cannon confirms
9
the petitioner's interpretation of Section 102(a)(1)." This cannon
holds that the meaning of ambiguous words in a statute may be
0
informed by the language which surrounds them. Moreover, the
Supreme Court has held that "otherwise" and other analogous
linking terms may "relate and define" the language which precede
them.9 1 Therefore, the true purpose of the catchall provision "or
otherwise available to the public" is to clarify that the categories of
prior art directly preceding the catchall provision share the "key
92
characteristic" of disclosing the claimed invention to the public.
The Supreme Court's holdings in Seatrain Lines and
Parolinestrengthen this interpretation of the catchall provision.
In SeatrainLines, the Court held that every enumerated category
within the statutory language at issue should "be read in light of
the final, comprehensive category" which was intended to be a
"catchall provision."9 Additionally, in Paroline, the Court again
Supreme Court "should be limited to interpreting any ambiguous term in the
Patent Act").
85 Id.
86 Id.
7

35 U.S.C 102(a)(1).

8

See Brief for Petitioner at 18, Helsinn, 139 S. Ct. 628.

8

Id. at 20

90 Id.

"' Id. at 19.
92

Id

Id. at 21.
94 Federal Maritime Commission v. Seatrain Lines, 411 U.S. 726, 734
9'

(1973).
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emphasized the idea that "enumerated provisions in a statute must
be read in light of a catchall provision that follows them.""
Teva argued that the noscitur a socils doctrine may not
apply where no ambiguity exists in the statutory language.96 It
further argued that Helsinn's reliance on Seatrain and Paroline
was misplaced given that the catchall provision within § 102(a) did
not "apply as much to the first and other words as to the last.""
However, both of these arguments are without merits. First, given
that each category of prior art shares the characteristic of public
disclosure in the post-AIA on-sale bar, the catchall provision does
apply equally to all the terms which precede it." Second, the
Supreme Court itself conceded in the Helsinn opinion that it had
not previously explored the effect of confidential sales on a patent's
validity under the AIA. 9 Furthermore, the Federal Circuit
refrained from addressing this issue in its brief as well.'o The
hesitancy of both the Supreme Court and Federal Circuit in
analyzing the language of the post-AIA on-sale bar suggests that
Teva was incorrect in asserting that there was no ambiguity in the
statutory language. The language of the post-AIA on-sale bar
needed to be informed by the preceding language as Helsinn
correctly asserted. Unfortunately, the Supreme Court refrained
from analyzing the statutory language in this way and therefore
their decision was inconsistent with the plain-text interpretation of
the post-AIA on-sale bar language.
B. The CourtIgnored CongressionalIntent Behind the Post-AIA
On-sale Bar Language
The most disappointing aspect of the Court's decision in
Helsinn was its refusal to thoroughly discuss the Congressional
intent behind the post-AIA on-sale bar language.101 The Court
merely stated that if Congress had intended to change the meaning
of the on-sale bar they would have done so explicitly. 102 However,
by ignoring the drafting history of the AIA completely, the Court
fails to realize that Congress did indeed clarify that the purpose of
the catchall provision was to inform the meaning of the preceding
" Paroline v. United States, 572 U.S. 434, 477 (2014).
Brief for Respondent at 19, Helsinn, 139 S. Ct. 628.

96

* Id. at 35.

* See Brief for Petitioner at 18, Helsinn, 139 S. Ct. 628.
99 See Helsinn, 139 S. Ct. at 634.

100 See Helsinn, 855 F. 3d at 1368.
101 See Helsinn, 139 S. Ct. at 634.
102

Id.
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categories of prior art. Congress never intended for confidential
sales to qualify- as prior art under the post-AIA on-sale bar.
In enacting the AIA, Congress consulted with prominent
members of the patent community as well as the USPTO.1 o3 The
Act went through many revisions before passing in 2011.104
Congress consistently reiterated its belief that sales or offers for
sales must be made public to qualify as prior art in every version
of the Act.10 The House Judiciary Committed stated in its
"favorable report of the AIA" that the catchall provision, "or
otherwise available to the public," was included "to emphasize the
fact that [prior art] must be publicly accessible."10 6 Moreover, the
final Committee Report for the AIA cited floor remarks from
Senator Jon Kyl and Senator Patrick Leahy, one of the bill's
sponsors, which noted that it was Congress's intent, that the
meaning of prior art under the ALA must necessarily include public
This point was also strongly conveyed by
disclosure.10
Congressman Lamar Smith, another one of the bill's sponsors, in
his amicus curiae brief in support of the petitioner. 108
The Supreme Court echoed the argument made by Teva
that if Congress had intended to change the meaning of the on-sale
bar it would not have left the "on sale" language unchanged.o
However, Congressman Smith noted in his brief that language
such as "prior art" was reused from the previous statute and this
did not mean that "prior art" had the same definition as it did
before the passage of the AIA."10 Congressional intent to preserve
the meaning of a term may not be construed from the reuse of the
term from the repealed statute alone."' The on-sale bar "must be
construed in its new statutory context."' 1 2
Lastly, in holding that confidential sales qualify as prior art
See Brief for The Intellectual Property Law Association of Chicago
("IPLAC") as Amicus Curiae Supporting Petitioner at 7, Helsinn, 139 S. Ct. 628.
0
Id at 9.
103

105

Id

Brief for United States as Amicus Curiae Supporting Petitioner at 24,
Helsinn, 139 S. Ct. 628.
10

10' See Matal, supra note 44.
108 See Brief for Congressman

Lamar Smith as Amicus Curiae Supporting
S.
Ct.
628.
139
Petitioner at 2, Helsinn,
109 See Helsinn, 139 S. Ct. at 634; see also Brief for Respondent at 26,
Helsinn, 139 S. Ct. 628.
no See Brief for Congressman Lamar Smith as Amicus Curiae Supporting
Petitioner at 29, Helsinn, 139 S. Ct. 628.
nId.
112

I

at 30.
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under the AIA, the Supreme Court interfered with one of
Congress's primary goals in enacting the legislation. Congress
hoped to synchronize the United States patent system with the
enactment of the AlA. 113 Patent systems which have adopted the
"first-inventor-to-file" system hold that prior art must make a
claimed invention available to the public.11 4 Therefore, the
Supreme Court's interpretation that prior art need not be
publically disclosed under the AIA directly conflicts with
Congressional intent to synchronize the United States patent
system with those of other nations.
IV. THE CHILLING EFFECT OF HELSINNON RESEARCH
AND DEVELOPMENT EFFORTS BY SMALL AND
MIDSIZE PHARMACEUTICAL COMPANIES
Helsinn will undoubtedly have many negative implications
for inventors of all kinds but its effect on small and midsize
pharmaceutical companies will be particularly detrimental." The
development of many drugs often begins with small and midsize
pharmaceutical companies.1 16 It may take "10 to 15 years and
approximately $2.6 billion to successfully bring a new drug to the
market.""' Due to high costs and limited resources, these small
and midsize pharmaceutical companies often rely on business
partners to continue with the research and development of their
drugs." Furthermore, when the business partner is a publicly
traded company, they "may be required to disclose the existence of
any such transactions under federal statutes such as the Securities
Exchange

Act

of

1934."119

In fact, Helsinn is illustrative of this business model.
Palonosetron was first created by researchers in California.1 20 It
was then acquired by Roche and next by Helsinn. 1 21 Helsinn later

n1 See Brief for Petitioner at 3-4, Helsinn, 139 S. Ct. 628.
114 Id. at 33.
"' See Brief for Massachusetts Biotechnology Council ("MassBio") as
Amicus Curiae Supporting Petitioner at 11-12, Helsinn, 139 S. Ct. 628.
116

Id

"17

Id.

11

Id at 13.
Id at 14.

119
120

See Helsinn Healthcare SA. v. Dr. Reddy's LabratoriesLtd., No. 113962, 2016 WL 832089, at *5 (D.N.J 2016).
121 Id. at 8, 10-12.
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teamed up with Oread to continue developing the product.12 2
Finally, Helsinn had to partner with MGI to continue with Phase
III of the project when Oread suddenly went out of business. 12 3
Given the fact that MGI was a publicly traded company, it had to
disclose the agreements it had entered into with Helsinn.12 4 In this
way, the invention was passed from entity to entity. This is the
reality of drug development in the United States. Thus, the reliance
on confidential sales by small and midsize pharmaceutical
companies is not an attempt to bypass patent laws. It is often the
only way in which an inventor can continue to finance the research
and development of their new drug product. As such, "63% of new
drugs approved between 2013 and 2018 and more than threequarters of the new molecular entities approved in 2017 originated
in small and midsize companies."1 2 5
The decision in Helsinn therefore unfairly targets the
of these small and midsize
research and innovation
pharmaceutical companies. The Federal Circuit held in Medicines
Co. that the on-sale bar should not be applied differently to
inventors "depending on whether their business model is to
outsource manufacturing or to manufacture in-house." 12 6 This is
precisely what has occurred in the decisions rendered by the
Federal Circuit and the Supreme Court in Helsinn. The holdings
of these Courts will have a "chilling effect that disproportionately
harms small and midsize biotechnology companies." 1 2 7
Finally, not only will the decision in Helsinn affect future
research and development of drugs, it will also call into question
"the validity of many pending and granted patents." 2 8 The
USPTO interpreted the on-sale bar of the AIA to exclude
confidential sales and included this interpretation in guidelines to
patent examiners. 1 29 Many small and midsize pharmaceutical
companies may be dragged into unnecessary litigation for patents
which were previously understood as being valid.

Id. at 14-15.
Id. at 27.
124 Id. at 28.
125 Adam Houldsworth, SCOTUS ruling is a blow to snall companies on
the frontline of life sciences innovation, IAM, https://www.iam-media.com/lawpolicy/scotus-ruling-blow-small-companies-frontline-life-sciences-innovation.
126 See Medicines, 827 F. 3d at 1378-1379.
127 See Brief for Massachusetts Biotechnology Council ("MassBio") as
Amicus Curiae Supporting Petitioner at 14, Helsinn, 139 S. Ct. 628.
128 See Houldsworth, supranote 125.
129 See Brief for Petitioner at 8, Helsinn, 139 S. Ct. 628.
122
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CONCLUSION

Patent law in the United States is a fine balance between
promoting innovation and preventing monopolization. The on-sale
bar is one of the ways in which Congress strikes this balance.
Congress thoughtfully and purposefully added the catchall
provision in the on-sale bar of the AIA. It was done with the
intention of doing away with unnecessary "traps" for inventors in
the form of needless litigation due to confidential sales. 130
However, the Court's decision in Helsinn seriously contradicts this
intention and the repercussions of this decision will be felt most
strongly by small and midsize pharmaceutical companies. In
overstepping its authority and ignoring Congressional intent, the
Court has interfered with Congress's goal to streamline American
patent laws and threatened the research and development of many
potentially valuable drugs.

130

See Matal, supra note 44.

